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SympathectomyIntroduction: Mixed connective tissue disease (MCTD) is an autoimmune disease that is rare in children.
The disease is presented with complex clinical features, so early diagnosis is challenging. Herein we
describe the management and outcome of a girl with MCTD associated with macrophage activation syn-
drome (MAS) and refractory Raynauds’ phenomenon.
Case report: A 13-year-old girl was admitted to the pediatric rheumatology ward with mild fever, reduced
appetite, 6 kg weight loss (body mass index 15.8), digital ulcers, sclerodactyly, scleroderma, dysphagia,
gastroesophageal reflux and arthralgia. She also had photosensitivity, Raynaud’s phenomenon, painless
oral ulcers, and malar rash. She developed arthritis of the knees and ankles with limited range of motion.
Spirometry showed a restrictive pattern. There was speckled antinuclear antibodies (ANA; 1/1260) and
positive b-2-glycoprotein, U1-ribonucleoprotein (U1-RNP), anti-Scl-70 and anti-Ro52 antibodies. Anti-
double stranded deoxyribonucleic acid and anti-cyclic citrullinated protein antibodies were negative.
Based on clinical and laboratory findings, MCTD was confirmed. The child was treated with steroid,
vasodilators, and immunosuppressives. She had an attack of salmon pink rashes, spiky fevers, Koebner
phenomenon, serositis, and organomegaly and the diagnosis of associated MAS was held. The patient
was treated with pentoxifylline, prednisolone, methotrexate, low dose aspirin, nifedipine, and hydroxy-
chloroquine. On follow up there was refractory digital ulcers and Raynaud’s phenomenon; transthoracic
endoscopic sympathectomy was performed and digital ulcers and coldness resolved.
Conclusion: MCTD may present with a myriad of rheumatic manifestations and in association with MAS
the diagnosis and management may be challenging. Refractory Raynauds’ phenomenon may remarkably
improve on transthoracic sympathectomy.
 2019 Publishing services provided by Elsevier B.V. on behalf of Egyptian Society of Rheumatic Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).1. Introduction
Juvenile mixed connective tissue disease (MCTD) is a rare
autoimmune disease characterized by various overlapping features
such as juvenile idiopathic arthritis (JIA), polymyositis, cutaneous
scleroderma, systemic lupus erythematosus (SLE), and systemic
sclerosis (SSc) [1,2]. Fatigue, mild fever, cold fingers, paresthesias,
puffiness of the hands and fingers, arthritis, myositis, and skin rash
are main features of the disease [3]. The heart, lungs, and kidneyscan also be affected in the later stages of the disease [4]. MCTD is
an autoimmune disease with unknown underlying mechanism,
yet genetic factors may play a key role in its etiology [5]. Addition-
ally, certain viruses and chemicals may also contribute. It is note-
worthy that MCTD is very rare in children [6]. The disease
presents with features of more than one, usually two, connective
tissue diseases. Herein, we describe a 13-year-oldgirl admitted to
hospital with sequential complaints and findings compatible with
features of four rheumatologic disorders: SSc, SLE, JIA, and macro-
phage activation syndrome (MAS) which eventually, lead to the
final diagnosis of MCTD.
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A 13-year-old girl was admitted to the pediatric rheumatologic
ward, Mofid Children’s Hospital, Shahid Beheshti University of
Medical Sciences, Tehran, Iran with arthralgia of the knees and
wrists with back pain for 2 weeks duration and mild fever for
2 days. She also complained of reduced appetite, 6 kg weight loss
(weight: 40 kg; height: 150 cm; and BMI: 15.8 kg/m2), gastroe-
sophageal reflux, and upper painless dysphagia to solids, as well
as coldness, pain and peripheral cyanosis of fingers following con-
tact with water and cold weather from 2 months ago. Also, she
complained of muscle weakness. On physical examination, she
had restricted active and passive range of motion (ROM) of the
knees and ankles, swelling and warmness of the joints (arthritis),
sclerodactyly, and digital ulcers, as well as tenderness of sacroiliac
joints. The Patrick’s test for Flexion, ABduction, and External Rota-
tion (FABER) test was also positive. She also had malar rash, photo-
sensitivity, Raynaud’s phenomenon, and painless oral ulcers. The
muscle power of the upper and lower extremities was normal.
The informed consent has been obtained from parents of the girl.
Complete blood count (CBC) showed a white blood cell count of
5200  103/mm3 with absolute lymphopenia (624  103/mm3).
The erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), Immunoglobulins (Igs), muscle enzymes and complements
level were within normal limits. Serological tests for hepatitis,
infectious mononucleosis, cytomegalovirus (CMV), and parvovirus
B19 were negative. Antinuclear antibodies (ANA) were highly pos-
itive (ANA:1/1260) with speckled pattern. U1-ribonucleoprotein
autoantibody (U1-RNP) was increased (3+). The anti-double
stranded deoxyribonucleic acid (anti-ds-DNA) and also anti-cyclic
citrullinated protein antibodies (anti-CCP) were negative. b-2-
glycoprotein (b-2GP) antibodies (IgM and IgG) were three times
more than normal concentration. Topoisomerase I (Scl-70) and anti
Ro antibodies (Ro52) had been increased (2+ and >200 U/ml
respectively).
Her chest X-ray, echocardiography, abdominal and pelvic ultra-
sound were normal. Lung high-resolution computed tomography
(HRCT) was normal; however, a restrictive pattern was observed
in her lung on Spirometry test analysis. Bone mineral densitometry
revealed low bone mineral content (with Z score 3.3). MCTD was
eventually diagnosed according to the increased levels of ANA,
b-2GP antibodies, U1-RNP, Scl-70 and Ro52, as well as the presence
of SSc and SLE according to the classification and diagnostic
criteria [7].
The patient had received prednisolone (0.5 mg/kg/day),
methotrexate (MTX) (10 mg/m2/w), hydroxychloroquine (HCQ)
(6 mg/kg/day), naproxen (15 mg/kg/ day) and nifedipine
(0.25 mg/kg/day). Pamidronate (1 mg/kg/day) was also infused
for 3 days every three months. On monthly follow-up, arthritis
was resolved after 3 months. Furthermore, photosensitivity was
resolved. Malar rash and oral ulcers were negative and her weight
had been increased by 2 kg after 3 months. At the end of 4th
month, the patient developed deep pain on the right hand from fin-
gers tip to the clavicle besides digital ulcers and puffiness. Then she
was admitted to hospital and started treatment with alprostadil
(10 mg/kg/day for 5 days) and heparin. Furthermore, she received
rituximab (500 mg/m2/day) two times biweekly. After discharge,
pentoxifylline, antiplatelet dose of acetylsalicylic acid (ASA) and
warfarin were added.
Three months later, the case was re-admitted with high-grade
fever, headache, vomiting and lethargy. Laboratory investigations
revealed leukocytosis, neutrophilia, and increased levels of ESR
and CRP. Lumbar puncture (LP) was performed to examine the
cerebrospinal fluid (CSF) analysis and revealed a normal result.CSF and blood cultures, urinalysis, and viral serologic markers were
also negative. Chest x-ray, echocardiography, abdominal and pelvic
ultrasound results were normal. During hospitalization, she devel-
oped high fever spikes (>39 C) along with the salmon-colored
rash. Koebner’s phenomenon was positive. On the 5th day after
admission, the patient presented respiratory distress and pul-
monary hemorrhage. She also had persistent fever, hep-
atosplenomegaly, serositis, cytopenia and a normal ESR.
The patient was then transferred to pediatric intensive care unit
(PICU) and received intravenous immunoglobulin (2 g/kg over
12 h), pulse methylprednisolone (30 mg/kg/day for three days),
and intravenous cyclophosphamide (CYC) (500 mg/m2) being diag-
nosed as systemic-onset JIA with macrophage activation syndrome
(MAS) according to international league against rheumatism (ILAR)
criteria for systemic JIA as well as the 2016 classification guidelines
for MAS complicating systemic JIA [8,9]. Elevated liver enzymes,
high triglycerides, hypofibrinogenemia, and the marked increased
serum ferritin level (6500 ng/ml) were revealed two days later.
Treatment with pentoxifylline, prednisolone, MTX, ASA, nifedipine,
and HCQ was also continued. Intravenous pulse CYC (500 mg/m2)
was continued till 6 months and then every 3 months. During
these periods, she developed fingers wounds several times and also
complained from pain and peripheral cyanosis of fingers; refrac-
tory Raynaud’s phenomenon. A right side transthoracic endoscopic
sympathectomy was performed which showed a good response.
Ten months later the same surgery was also done for left side
and the patient ulcers and coldness significantly resolved.3. Discussion
A 13-year-old girl with MCTD presenting by multiple manifes-
tations including muscle weakness, fever, Raynaud’s phenomenon
and arthritis has been reported. She had also malar rash, photosen-
sitivity and painless oral ulcers and gradually developed manifes-
tations of systemic JIA and MAS. Increased levels of b-2GP
antibodies, Scl-70, Ro52, ANA, and U1-RNP pointed to the possible
diagnosis of systemic-onset JIA, SSc and SLE making the MCTD a
potentially challenging diagnosis as the manifestations usually
occur sequentially over time. The common features of other rheu-
matic diseases add to the difficulty in defining the disease. The
patient was diagnosed as a case of MCTD in line with the various
classification criteria [7,10]. Although MCTD occurs worldwide
and affects people of all ages, it is rare in children [1,2]. Several
studies reported MCTD in children [11–15]. Yang et al. reported
two girls (10- and 13-year-old) with MCTD initially presenting
with JIA, muscle weakness, Raynaud’s, elevated creatine kinase
and liver enzymes, sclerodactyly, arthralgia, lymphadenopathy,
pericardial effusion, and paralytic ileus. Both had high serum titers
of ANA and were seropositive for anti-RNP [16]. In another study,
Latuśkiewicz-Potemska et al reported a 10-year-old girl with MCTD
presented with sclerodactyly and trophic damages of fingers
accompanied by Raynaud’s [14]. High levels of ANA and U1-RNP,
which present in most MCTD patients, were found reliable tests
for the diagnosis of the disease [2]. Nevertheless, these antibodies
may present in healthy people and in other disorders.
Treatment of MCTD is similar to that of SLE, autoimmune
myositis, and SSc; however, it depends on the severity of disease
symptoms. Some patients require continuous treatment, while
others need treatment only during periods of heightened disease
activity. Non-steroidal anti-inflammatory drugs (NSAIDs),
corticosteroids, HCQ, and immunosuppressive drugs (e.g. MTX
and azathioprine) are usually used for these patients [5]. Immuno-
suppressive drugs are usually used in moderate to severe cases.
V.J. Parvaneh et al. / The Egyptian Rheumatologist 41 (2019) 323–325 325Several studies have shown the beneficial effect of sympathectomy
in patients with Raynaud’s phenomenon [17–19]. MTX and CYC
have been used as immunosuppressives in the present case. She
received maintenance treatment with pentoxifylline, prednisolone,
MTX, ASA, nifedipine, pulse CYC, and HCQ. However, after treat-
ment with these drugs, she still suffered with a refractory Ray-
naud’s phenomenon. Eventually, right and left hands
transthoracic endoscopic sympathectomy was performed and the
patient’s symptoms resolved. The role of sympathectomy in refrac-
tory Raynaud’s phenomenon in adolescents has been reported [19].
Different approaches have been used including local (digital or
wrist block) or regional (cervical or lumbar) chemical, localized
digital microsurgery and transthoracic endoscopic sympathectomy
[18,20]. Sympathectomy should be reserved for patients with
refractory digital ischemia and ulcers.
In conclusion, MCTD may present with a myriad of rheumatic
manifestations and in association with MAS the diagnosis and
management may be challenging. Refractory Raynauds’ phe-
nomenon may remarkably improve on transthoracic
sympathectomy.
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